Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00145301
Status:
COMPLETED
Last Update Posted:
2012-05-21
First Post:
2005-09-01
Brief Title:
52 Week International Multi-center Randomized Double-blind Double-dummy Parallel-group Clinical Trial to Compare Retention on Treatment Safety Tolerability Efficacy of Lumiracoxib 100 mg od Lumiracoxib 100 mg Bid Celecoxib 200 mg od in Pts With Primary OA of Hip Knee Hand or Spine
Sponsor:
Organization:
Novartis
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
3036
Enrollment Type:
None
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE3 |
Observational Models:
Time Perspective List:
Who Masked List: